Oct 16, 2017
New Clinical Data and Microbiome Research from Rebiotix's Phase 2 Program for RBX2660 Highlighted at the World Congress of Gastroenterology at ACG2017
Oct 12, 2017
Rebiotix Announces New RBX2660 Data Including a Novel Microbiome Biomarker Analysis to be Presented at the World Congress of Gastroenterology at ACG2017
Oct 04, 2017
Presentations at ID Week(TM) 2017 Highlight Clinical Results and Microbiome Analysis of Patients Treated in Rebiotix's RBX2660 Phase 2 Studies
Sep 06, 2017
AvidBiotics' Scientists Co-author Publication in "Science Translational Medicine" Describing A New Class of Targeted Antibacterial Agents for Clostridium difficile
Sep 06, 2017
Rebiotix Appoints Edward S. Burd, Ph.D., to Head of Regulatory Affairs
Aug 23, 2017
Rebiotix to Present at BioCentury's 24th Annual NewsMakers in the Biotech Industry Conference
Aug 07, 2017
Rebiotix Announces First Patient Enrolled in Phase 3 Clinical Trial of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection
Jul 24, 2017
Luminex Corporation Receives FDA Clearance for ARIES C. difficile Assay
Jun 20, 2017
New Research Reveals OTC Probiotic Reduces Cytotoxicity Of Potentially Life-Threatening Bacteria
Jun 20, 2017
Rebiotix Continues Management Team Expansion with Appointment of Greg Fluet as Chief Business Officer
Jun 07, 2017
Rebiotix Data Presented at ASM Microbe 2017 Show RBX2660 Treated Patients' Clinical Success Correlates with Improved Microbiome Diversity
Jun 05, 2017
Ultra-Sensitive C. Difficile Assay In Development By Singulex Demonstrates Potential To Improve Diagnosis In Pilot Studies
Jun 01, 2017
Rebiotix's Phase 3-Ready RBX2660 to be Featured in Multiple Posters at ASM Microbe 2017
May 30, 2017
TECHLAB® To Showcase Its C. DIFF QUIK CHEK COMPLETE® At 2017 American Society For Microbiology Microbe Meeting